Three Studies Investigate the Role of Psychedelics in Treating OCD

April 8, 2021 11:05:09

Recent psychedelic research has led to significant breakthroughs in the field. The substances have been found to be useful in treating various mental health conditions such as depression as well as addiction. Additionally, new research has found that psilocybin, which is the active ingredient in magic mushrooms, is useful in treating obsessive-compulsive disorder (“OCD”).

There are three studies looking into the use of psilocybin to decrease the symptoms of obsessive-compulsive disorder. While each study is using different treatment techniques, the evidence they’ve uncovered may be crucial in helping researchers understand the therapeutic mechanism behind psychedelic drugs.

Generally, OCD is characterized by a failure to release or surrender control, which is the opposite of what a full psychedelic experience demands. A comedian based in L.A., Adam Strauss, stated that individuals who suffer from OCD usually try to control their experiences in a way that becomes painful and counterproductive. Strauss used psychedelics to overcome obsessive-compulsive disorder.

He explained that his experimentation with low and moderate psychedelic doses led him to the discovery that higher doses of hallucinogenic mushrooms were the most efficacious at providing him with the most therapeutic value, which allowed him to let go.

Strauss got the idea to treat his obsessive-compulsive disorder with psychedelics from a study that was published in the “Journal of Clinical Psychiatry” in 2006. In the study, nine patients had psilocybin administered to them roughly four times each, at doses which ranged from very low to hallucinogenic. All patients exhibited immediate improvement in their symptoms of OCD after a single session. The drug that was used during the study was also found to be well tolerated and safe.

Of the three current studies, the first is being led by Professor Francisco Moreno, from the psychiatry department of the University of Arizona. He happens to be the same researcher who led the aforementioned 2006 study. In an email, Moreno noted that his study, which had been launched in 2017, was affected by the 2020 pandemic but would be resuming soon.

Of the other two studies, one is being conducted by Benjamin Kelmendi, a principal researcher from Yale University. Kelmendi, who is an assistant professor of psychiatry, stated that the study would resume after a nine-month period, with projections showing that it may be completed in early 2022. Similar to Moreno’s study, Kelmendi’s study will measure the effects of psilocybin and compare those effects to clinical outcomes for obsessive-compulsive disorder.

The third study, which will focus on OCD and psilocybin, is being led by David Nutt, a psychedelic researcher from the Center for Psychedelic Research at the Imperial College London.

As more studies unearth the therapeutic abilities of psychedelics, many companies will need to get involved to bring the needed drug formulations to market. XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) is already hard at work studying ways to integrate psychedelic active pharmaceutical ingredients into existing clinical programs that are aimed at addressing the unmet mental health treatment needs around the world.

NOTE TO INVESTORS: The latest news and updates relating to XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) are available in the company’s newsroom at

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published:

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
415.949.5050 Office

PsychedelicNewsWire is part of the InvestorBrandNetwork.